Long-term cognitive dysfunction in the rat following docetaxel treatment is ameliorated by the phosphodiesterase-4 inhibitor, rolipram.

Long-term cognitive dysfunction in the rat following docetaxel treatment is ameliorated by the phosphodiesterase-4 inhibitor, rolipram. Our latest paper [download] focuses on chemobrain – the mental fog or fuzziness that can accompany and follow chemotherapy. Behav Brain Res. 2015 May 1;290:84-89. doi: 10.1016/j.bbr.2015.04.044. [Epub ahead of print] Callaghan CK, O’Mara SM. Clinical studies report evidence of long-term… Read More

Semliki Forest virus-mediated gene therapy of the RG2 rat glioma

Neuropathol Appl Neurobiol. 2010 Dec;36(7):648-60. doi: 10.1111/j.1365-2990.2010.01110.x. [Download the paper] Semliki Forest virus-mediated gene therapy of the RG2 rat glioma. Roche FP, Sheahan BJ, O’Mara SM, Atkins GJ. AIMS: Glioblastoma multiforme is the most common and most malignant adult brain tumour. Despite numerous advances in cancer therapy there has been little change in the prognosis… Read More

Maybe neuroscience needs ‘malbrain’ to complement cell biology’s ‘cancer’ in the public mind…***

Previously, I wondered why there was no hue-and-cry over the huge disinvestment in brain research over the past decade, and why, by comparison, cancer research does well.* ‘Cancer‘ is understood by the public at large, by the political establishment, by the pharmaceutical companies and a host of other stakeholders as a single-word issue of great and pressing concern to… Read More

Why the lack of spending on neuroscience? A comparison with cancer research spending, and a neologism (‘malbrain’).

Previously, I wondered why there is no hue and cry about the loss of research budgets for neuroscience. Comparing research spends between areas is not easy. This paper (Sobocki et al., 2006) has some data: Abstract This article is a markedly condensed summary of a longer report [Resource allocation to brain research in Europe (RABRE), part 2] that… Read More

Why no public hue and cry over neuroscience disinvestment? Does nobody care about brain diseases and brain disorders?

The past few years have seen astonishing disinvestment by the pharmaceutical industry in neuroscience research. There have been closures announced of whole research divisions by virtually all the major pharmaceutical companies. They are ceasing research in neuroscience because of its complexity, cost, and their current lack of capacity to deliver a pipeline of meaningful market… Read More